Combined molecular targeting for cancer therapy: A new paradigm in need of molecular imaging

Journal of Nuclear Medicine

Volumn 47, Issue 1, 2006, Pages 4-5

  DeNardo, Sally J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIZUMAB; DOXORUBICIN; PENTETATE INDIUM IN 111; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; METASTASIS; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; DRUG DELIVERY SYSTEM; GENETIC PROCEDURES; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NOTE; RADIOIMMUNOTHERAPY; SCINTISCANNING;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 34248674629     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Capello A, Krenning EP, Bernard BF, Breeman WAP, Erion JL, de Jong M. Anticancer activity of targeted proapoptotic peptides. J Nucl Med. 2006;47:122-129.
2. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (apolizumab). Semin Oncol. 2002;29:81-86.
3. 90Y-labeled HLA-DR antibodies. Clin Cancer Res. 2005;11:7075s-7079s.
4. 90Y-CHX-A″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res. 2005;11:7080s-7086s.
5. 90Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med. 2001;42:1841-1846.
6. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-1713.
7. 3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
8. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
9. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 1999;397:534-539.
10. DeNardo SJ, Burke PA, Leigh BR, et al. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm. 2000;15:71-79.
11. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
12. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
13. 18F]galacto-RGD. PLoS Med. 2005;2:244-252.
14. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.